Gilde Healthcare is a specialized healthcare investor with two primary fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund targets innovative healthtech and therapeutics companies in Europe and North America, while the Private Equity fund focuses on profitable European lower mid-market healthcare providers, suppliers, and service providers. Their overarching investment philosophy is to support businesses that enable better care at lower cost.
50% of their portfolio is in Biotech & Life Sciences. Deal activity increased 40% year-over-year (7 deals in the last 12 months). Their most common stage is series-b (40% of deals). Average disclosed round size is $67.0M (across 19 rounds with reported amounts).
Portfolio
20
Fund Size
$2.6B
Top Stage
Series B
Last 12 Mo
7
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Endovascular Engineering, Inc. | Series C | $80M | Apr 2026 |
 Big Health | Unknown | $23.7M | Feb 2026 |
| PProVerum | Series B | $68.6M | Aug 2025 |
 ProVerum Limited | Series B | $80M | Aug 2025 |
 GT Medical Technologies, Inc. | Series D | $53M | Jul 2025 |
 SpliceBio | Series B | $135M | Jun 2025 |
 SpyGlass Pharma | Series D | $75M | Jun 2025 |
| SShoulder Innovations | Series E | $40M | Mar 2025 |
| GT Medical Technologies, Inc. | Series D | $37M | Jan 2025 |
 Noema Pharma | Series B | — | Dec 2024 |
 Adcendo ApS | Series B | $135M | Nov 2024 |
 Purespring Therapeutics | Series B | $105M | Oct 2024 |
 Karius | Series D | $100M | May 2024 |
 Tagworks Pharmaceuticals | Series A | $65M | Jun 2023 |
| GT Medical Technologies, Inc. | Series C | $45M | Mar 2023 |
| SpliceBio | Series A | $50M | Feb 2022 |
| Noema Pharma | Series A | $59M | Dec 2020 |
 Withings | Series B | $60M | Jul 2020 |
| Big Health | Series B | $39M | Jun 2020 |
| CCalypso Biotech | Series A | $22.6M | Feb 2019 |
Top Co-Investors
Last updated: 4 May 2026